乌鸦传媒

Stefan Anker, MD, says it should be "the new paradigm" for treatment of patients with LVEF 50%

Clyde Yancy, MD, welcomes the discussion, but warns there are still more questions than answers

No safety concerns seen with the SGLT2 inhibitor

But misses key secondary endpoint of reduction of CV death